Phase 2a trial in 130 participants with mild-to-moderate dementia with Lewy bodies: zervimesine 100 or 300 mg vs placebo for 26 weeks; discontinuation for adverse events was 4.5%, 16.3% and 4.8%. Efficacy was assessed only as exploratory outcomes.
RCTn = 130
Galvin et al. Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB)